Posted by Michael Wonder on 16 Dec 2019
The reimbursement for medicines will continue to increase in 2019
13 December 2019 - According to TLV's forecast, the reimbursement from the side agreements is estimated to amount to SEK 3,090 million in 2019.
This is an increase corresponding to SEK 316 million compared to 2018. The main reason for the increased reimbursement is new side agreements within the pharmaceutical group TNF inhibitors.
The reimbursement for the hepatitis C drug group is expected to be significantly lower than in 2018, due to a lower number of patients treated and reductions in the set prices.
